Tamoxifeno 10 mg 50 comprimidos Teva

O que é Tamoxifeno 10 mg 50 comprimidos Teva?

Fabricante: TEVA, Turquia
Substância: Citrato de Tamoxifeno
Embalagem: 1 x 50 comprimidos (10 mg/comprimido)

Propriedades farmacológicas:
Indicações:
Câncer de mama
Terapia adjuvante: Tamoxifeno é indicado após mastectomia total ou mastectomia segmentar, dissecção axilar e radioterapia em mulheres com câncer de mama sem linfodenopatia axilar. O tamoxifeno também é indicado em mulheres na pós-menopausa com linfodenopatia após mastectomia total ou matectomia segmentar, dissecção axilar e radioterapia.

Tratamento avançado de doenças: O tamoxifeno é eficaz no tratamento do câncer de mama avançado em mulheres. O tamoxifeno é uma alternativa à oforectomia ou irradiação ovariana em mulheres com câncer de mama na pré-menopausa.

Contra-indicações:
É contraindicado em gestantes com hipersensibilidade ao tamoxifeno.

Advertências/Precauções:
Tamoxifen should be used under the supervision of a physician experienced in hormonal cancer chemotherapy. Premenopausal women taking tamoxifen are at risk of becoming pregnant because Tamoxifen causes ovulation. Visual disturbances such as changes in the comea, cataracts and retinopathy were observed. Hypercalcemia has been reported in breast cancer patients with bone metastases when combined with estrogens and adrogens. Appropriate precautions are taken and Tamoxifen treatment is discontinued if necessary. Once hypercalcemia is controlled, treatment may be resumed under reduced dose or low dose prednisone.

An increase in the occurrence of endometrial changes such as hyperolasis, polyp and endometrial cancer has been observed in tamoxifen treatment. Previously used or currently using Tamoxifen; Patients with abnormal vaginal bleeding, menstrual irregularity, vaginal discharge and pain and pressure on the pelvis should be examined immediately. Tamoxifen should be used with caution in harvesting with leukopenia and thrombocytopenia. Periodic whole blood counts including erythrocyte are recommended in patients using the drug. Periodic liver function tests should be performed. Periodic serum triglyceride and cholesterol measurements are recommended in patients with hyperlipoproteinemia. Periodic liver function tests should be performed. Periodic serum trglyceride and cholesterol measurements are recommended in patients with hyperlipoproteinemia. If abnormal vaginal bleeding occurs, this should be reported to the physician and should be investigated. Tamoxifen has been reported to be carcinogenic in animals, although the findings in humans are not sufficient. The potential carcinogenic potential for humans should be considered when taking tamoxifen.

Uso na gravidez e lactação: o tamoxifeno não deve ser usado durante a gravidez. Se o medicamento for usado durante a gravidez ou engravidar durante o uso do medicamento, a paciente deve ser informada dos riscos potenciais, incluindo aborto espontâneo, defeitos congênitos, mortes fetais e sangramento vaginal. Recomenda-se não usar tamoxifeno durante a lactação.

Efeitos colaterais/efeitos adversos:

Adverse reactions due to tamoxifen are mild or infrequent and do not require discontinuation of treatment. If adverse reactions are severe, they can be controlled with a simple dose reduction without losing control of the disease. If side effects do not respond, discontinue of the treatment may be necessary. Side effects during long-term treatment with tamoxifen are not as severe as the side effects of androgens and estrogens used in the treatment of breast cancer. The drug is classified as antiestrogenic effect (redness, vaginal, bleeding, pruritus vulva) or general effects (gastrointestinal intolerance, tumor pain, dizziness, skin rash) and rare effects (fluid reaturation and partial hair loss). Tamoxifen causes changes in liver enzyme levels and causes liver disorders such as liver fat, cholestasis, hepatitis and hepatic necrosis. Hot flashes are nausea and / or vomiting. These reactions may occur in 25% of patients. Less frequently reported adverse reactions are: Grenitourinary system; vaginal bleeding and discharge, menstrual irregularities Bone and soft tissue; Severe bone and tumor pain may occur during tamoxifen treatment and sometimes these effects are associated with a good tumor response. Analgesics may be needed for pain. Patients with soft tissue disease may have an increase in the size of pre-existing lesions. This increase is sometimes accompanied by significant erythema in and around the lesion, and may also occur new lesions. Bone pain burns appear and disappear immediately after the start of treatment. Adverse reactions reported quarterly; Thromboembolic findings (deep vein thrombosis, pulmonary embolism, superficial phlebitis) have been reported rarely during tamoxifen treatment. It is known that these findings occur in patients with increased tumor formation. The causative relationship of tamoxifen has not been established. Menstruation of premono-posal women using tamoxifen for breast cancer treatment is prevented. Reversible ovarian cysts were observed in women treated with 40 mg Tamoxifen twice daily for short term.

Outras reações adversas pouco frequentes; Hipercalcemia, edema periférico, ausência de sabor dos alimentos, prurido vulvar, depressão, tontura e dor de cabeça.
Interações medicamentosas:
Tamoxifen / Anticoagulants; When tamoxifen is used in combination with coumadine type coagulants (eg Warfarin), there may be a significant increase in anticoagulant effect. To compensate for safe anticoagulation, a significant reduction in the daily dose of anticoagulant may be necessary. Life-threatening interactions have been reported. Tamoxifen / Antineoplastics, Tamoxifen, N-desmethyl tamoxifen c and 4-hydroxytamoxifene were found to be potent inhibitors of liver cytochrome p 450enzyme system. The effect of Tamoxifen on the metabolism and excretion of cyclophodfamide and other antineoplastic drugs that require oxidase enzyme system for effect is not known.

Dosagem e administração:
Duas vezes ao dia (manhã e noite) 10-20 mg. A primeira resposta ao tratamento é geralmente alcançada 1-3 meses após o início. Uma dose diária superior a 20 mg é benéfica nos casos em que a doença progride e o tratamento é aprovado.

Aviso!

Usando esteróides anabolizantes com ou sem conhecimento sobre o assunto pode causar danos ao seu corpo. Eles até podem causar a morte. Você deve ter cuidado ao fazer exames antes, durante e depois do uso de esteróides anabolizantes. Nossa empresa alerta sobre todos os riscos do uso de esteróides e não aceitamos qualquer responsabilidade sobre problemas e consequências de saúde. Portanto não vendemos quem não tenha mais de 20 anos.